Skip to main content
    E

    EXACT Sciences Corporation (EXAS)

    Official site

    DIAGNOSTICS & RESEARCH

    $104.91
    +0.00 (+0.00%)

    Last updated: Mar 24, 2026 at 5:00 PM ET

    EXACT Sciences Corporation (EXAS) Financials: Revenue, Profit and Cash Flow

    Updated Feb 13, 2026. Financial statements from company filings, amounts in US dollars.

    EXACT Sciences reported revenue of $3.25B for the fiscal year ended Dec 31, 2025, up 17.7% from the year before. That year, net income was -$207.95M with a net margin of -6.4%, operating cash flow was $491.44M and free cash flow was $281.78M. The quarter ended Dec 31, 2025 had revenue of $878.38M and net income of -$85.95M.

    Revenue and Margins

    The operating margin was -6.4% in the fiscal year ended Dec 2025, the highest of the 9 years shown with an operating margin. Over the 9 years to Dec 2025, revenue grew from $99.38M, a compound annual rate of 47.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$3.25B+17.7%69.7%-6.4%-6.4%
    Dec 2024$2.76B+10.4%69.5%-38.0%-37.3%
    Dec 2023$2.50B+19.9%70.5%-8.6%-8.2%
    Dec 2022$2.08B+17.9%68.3%-28.5%-29.9%
    Dec 2021$1.77B+18.5%74.0%-48.4%-33.7%
    Dec 2020$1.49B+70.2%76.2%-51.5%-55.2%
    Dec 2019$876.29M+92.8%75.3%-26.7%-24.3%
    Dec 2018$454.46M+70.9%74.3%-35.1%-38.5%
    Dec 2017$265.99M+167.7%70.6%-44.5%-43.0%
    Dec 2016$99.38MN/A54.5%-170.1%-168.3%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Dec 2025, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$3.25B$2.76B$2.50B$2.08B$1.77B$1.49B$876.29M$454.46M$265.99M$99.38M
    Cost of revenue$984.24M$840.15M$737.56M$661.36M$458.76M$354.32M$216.72M$116.64M$78.31M$45.20M
    Gross profit$2.26B$1.92B$1.76B$1.42B$1.31B$1.14B$659.58M$337.82M$187.68M$54.18M
    Research and development$523.00M$431.21M$426.93M$394.19M$385.65M$554.05M$139.69M$67.28M$42.10M$33.47M
    Operating income-$206.30M-$1.05B-$215.01M-$593.51M-$855.68M-$767.70M-$233.78M-$159.47M-$118.31M-$169.02M
    Net income-$207.95M-$1.03B-$204.15M-$623.51M-$595.63M-$823.61M-$213.09M-$175.15M-$114.40M-$167.21M
    EBITDA$57.05M-$833.84M$24.31M-$415.38M-$643.55M-$594.66M-$185.29M-$110.22M-$104.29M-$158.00M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Revenue$878.38M$850.74M$811.09M$706.78M$713.42M$708.65M$699.26M$637.52M$646.88M$628.34M$622.09M$602.45M
    Gross profit$615.83M$583.93M$562.45M$500.55M$492.59M$491.49M$488.32M$446.32M$391.70M$459.81M$465.10M$445.58M
    Operating income-$82.59M-$25.55M-$2.15M-$96.01M-$876.35M-$39.40M-$26.26M-$106.69M-$67.84M$6.85M-$76.93M-$77.09M
    Net income-$85.95M-$19.59M-$1.19M-$101.22M-$864.59M-$38.24M-$15.81M-$110.23M-$49.77M$794.00K-$81.03M-$74.15M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $2.33B exceeded cash and equivalents by $1.37B.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$5.86B$5.93B$6.47B$6.23B$6.23B$4.93B$3.51B$1.52B$598.56M$377.04M
    Current assets$1.56B$1.57B$1.19B$982.26M$982.26M$2.20B$553.94M$1.23B$487.22M$333.57M
    Cash and equivalents$956.00M$600.89M$605.38M$242.49M$242.49M$1.49B$177.25M$160.43M$77.49M$48.92M
    Total liabilities$3.46B$3.53B$3.33B$3.18B$3.18B$2.69B$1.22B$843.08M$78.14M$41.74M
    Short-term debt$0$249.15M$50.00M$0$19.71M$314.03M$834.00K$8.00K$182.00K$174.00K
    Long-term debt$2.33B$2.32B$2.31B$2.24B$2.24B$1.88B$827.64M$689.24M$4.27M$4.63M
    Shareholder equity$2.40B$2.40B$3.15B$3.04B$3.04B$2.24B$2.29B$680.94M$520.42M$335.30M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Total assets$5.86B$5.90B$5.80B$5.71B$5.93B$6.75B$6.67B$6.38B$6.47B$6.42B$6.36B$6.42B
    Total liabilities$3.46B$3.40B$3.33B$3.31B$3.53B$3.54B$3.48B$3.24B$3.33B$3.30B$3.30B$3.30B
    Cash and equivalents$956.00M$789.04M$657.10M$347.13M$600.89M$588.83M$530.18M$347.49M$605.38M$594.61M$604.36M$594.61M
    Shareholder equity$2.40B$2.50B$2.47B$2.40B$2.40B$3.21B$3.19B$3.13B$3.15B$3.12B$3.06B$3.12B
    Last 12 quarters

    Cash Flow

    In the fiscal year ended Dec 2025, free cash flow was 57.3% of operating cash flow.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow$491.44M$210.54M$156.12M-$223.56M-$102.24M$136.48M-$111.66M-$68.94M-$71.72M-$130.07M
    Capital expenditures$209.66M$180.99M$124.69M$214.46M$193.84M$476.50M$172.65M$150.09M$48.48M$14.85M
    Free cash flow$281.78M$29.55M$31.43M-$438.02M-$296.07M-$340.02M-$284.31M-$219.03M-$120.20M-$144.92M
    Dividends paidN/AN/A$169.52MN/A$37.51M$18.36M$17.18M$929.78M$5.10M$2.10M
    Investing cash flow$195.12M-$442.15M$49.68M$74.07M-$1.08B-$702.04M-$124.43M-$782.30M-$160.81M-$11.52M
    Financing cash flow-$338.09M$231.87M$159.77M$76.48M$8.47M$1.88B$253.18M$934.14M$260.96M$149.59M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Operating cash flow$151.69M$219.92M$89.02M$30.81M$47.06M$138.72M$107.06M-$82.31M$69.55M$24.36M$100.42M-$38.22M
    Capital expenditures$106.24M$29.90M$42.34M$31.17M$81.32M$26.16M$35.87M$37.65M$35.42M$25.19M$34.72M$29.36M
    Free cash flow$45.45M$190.03M$46.67M-$365.00K-$34.25M$112.56M$71.20M-$119.96M$34.13M-$826.00K$65.70M-$67.58M
    Last 12 quarters

    Frequently Asked Questions About EXAS

    What is EXACT Sciences' annual revenue?

    EXACT Sciences reported revenue of $3.25B for the fiscal year ended Dec 31, 2025.

    How fast is EXACT Sciences' revenue growing?

    Revenue was up 17.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 15.9%.

    Is EXACT Sciences profitable?

    No. EXACT Sciences reported net income of -$207.95M for the fiscal year ended Dec 31, 2025, with a net margin of -6.4%.

    How much free cash flow does EXAS generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of $491.44M minus capital expenditures of $209.66M produced free cash flow of $281.78M.

    How much debt does EXACT Sciences have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $2.33B, short-term debt of $0 and cash and equivalents of $956.00M.